作者: Gordon S Howarth , Cheryl A Shoubridge
DOI: 10.1016/S1471-4892(01)00098-4
关键词: Fibroblast Growth Factor 7 、 Biology 、 Keratinocyte growth factor 、 TGF alpha 、 Epidermal growth factor 、 Growth factor receptor inhibitor 、 Cancer research 、 Fibroblast growth factor receptor 2 、 Transforming growth factor, beta 3 、 Endocrinology 、 Growth factor 、 Internal medicine
摘要: Recently, glucagon-like peptide 2 has emerged as a potent stimulator of epithelial growth, joining insulin-like growth factor I, hepatocyte and keratinocyte potential treatment modalities for intestinal disorders associated with loss mucosal mass, such short bowel syndrome. Investigations into other members the expanded epidermal family, development more analogues, advances in enterally administered bioactive formulations further expands repertoire factors applicable to conditions insufficiency.